Also known as: Draganon, Ampamet, Memodrin
Aniracetam is a fat-soluble racetam nootropic that modulates AMPA receptors and is studied for its anxiolytic and cognition-enhancing properties. It is more potent than piracetam on a per-milligram basis.
Aniracetam is a lipophilic analog of piracetam developed by Hoffmann-La Roche in the 1970s. It acts as a positive allosteric modulator of AMPA-type glutamate receptors, enhancing synaptic transmission and long-term potentiation, key processes in learning and memory formation. Aniracetam also modulates cholinergic, dopaminergic, and serotonergic pathways, which may account for its anxiolytic properties observed in animal studies. Clinical trials in patients with cognitive impairment have shown improvements in attention, memory, and emotional stability. Due to its fat solubility, it has faster onset but shorter half-life than piracetam. Aniracetam is a prescription medication in parts of Europe (including under the name Ampamet in Italy) and Japan (as Draganon), while it is sold as a dietary supplement in the United States.
Aniracetam potentiates AMPA receptor activity, facilitating long-term potentiation and improving memory consolidation in clinical studies of cognitively impaired patients.
Animal studies demonstrate anxiolytic effects mediated through modulation of dopamine and serotonin, without the sedative side effects of benzodiazepines.
Divided into 2–3 doses, taken with a fat source
Fat-soluble: absorption is significantly improved when taken with meals containing dietary fat. Short half-life of 1–2.5 hours.
Precise dosing and convenience
Cost efficiency and flexible dosing
No product recommendations yet.
No reviews yet. Be the first to share your experience!